Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab Immunotherapy in Patients With Advanced Brain Cancer Including Gliomas and Meningiomas
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Interleukin-2 (Primary) ; Pembrolizumab (Primary) ; Tumour infiltrating lymphocyte therapies (Primary)
- Indications Glioma; Meningioma
- Focus Adverse reactions
- Sponsors Essen BioTech
- 17 Oct 2024 New trial record